Clinical outcomes in patients with recurrent or metastatic human papilloma virus-positive head and neck cancer

Rajan P. Dang, Valerie H. Le, Brett A. Miles, Marita S. Teng, Eric M. Genden, Richard L. Bakst, Vishal Gupta, David Y. Zhang, Elizabeth G. Demicco, Marshall R. Posner, Krzysztof J. Misiukiewicz

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Background: There are few data regarding the role of human papilloma virus (HPV) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Patients and Methods: A retrospective chart review was carried out using our electronic medical record (EPIC) for all patients diagnosed with HPV-positive R/M HNSCC between 2010 and 2014 with minimum of 6 months of follow-up in order to assess progression-free survival (PFS) and overall survival (OS). Results: We assessed 11 patients who underwent a variety of treatments. PFS and OS were 7 and 34+ months, respectively. Four patients (36%) were still alive and diseasefree (median OS of 39+ months). Three disease-free patients had been treated with taxane, platinum and 5-fluorouracil as aggressive curative systemic therapy. Another patient treated with TPF was disease-free for 25 months and died of disease at 42 months. Conclusion: Our study demonstrates favorable prognosis for patients with HPV-positive R/M HNSCC and that aggressive systemic treatment can lead to a prolonged disease-free period or possibly cure, even after metastasis.

Original languageEnglish
Pages (from-to)1703-1709
Number of pages7
JournalAnticancer Research
Volume36
Issue number4
StatePublished - Apr 2016

Keywords

  • HPV
  • Human papillomavirus
  • Metastatic
  • Oropharyngeal cancer
  • Recurrent

Fingerprint

Dive into the research topics of 'Clinical outcomes in patients with recurrent or metastatic human papilloma virus-positive head and neck cancer'. Together they form a unique fingerprint.

Cite this